Abstract
The patient access scheme (PAS) has been implemented as a formal part of the pricing and reimbursement environment in the United Kingdom (UK) since 2009, which aims to improve cost-effectiveness and enable patients to gain access to high-cost drugs and treatments. This study was to investigate the impact of the patient access scheme on the appraisals for the innovative medicines in Scottish Medicines Consortium (SMC) between 2011 and 2020.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
